Molecular Therapy
Volume 30, Issue 2, 2 February 2022, Pages 534-549
Original ArticleDual-antigen targeted iPSC-derived chimeric antigen receptor-T cell therapy for refractory lymphoma
Under a Creative Commons license
open archive
Graphical abstract
Keywords
CD19-CAR
dual-antigen targeted CART therapy
EBV-associated lymphoma
iPSC-derived CTL
LMP1
LMP2
rejuvenated CTL
dual CAR
iPSC-CART
“off-the-shelf” T cell therapy
Cited by (0)
- 11
Co-senior authors
© 2021 The American Society of Gene and Cell Therapy.